Immunohistochemistry Panel (7-IHC) at Lahore PCR Lab

Immunohistochemistry Panel (7-IHC) at Lahore PCR Lab

The Immunohistochemistry Panel (7-IHC) at Lahore PCR Lab is a highly specialized, state-of-the-art diagnostic pathology investigation used to identify specific cellular proteins (antigens) within tissue samples. By utilizing the precise binding affinity between antibodies and antigens, this advanced laboratory technique allows consultant pathologists to visualize the exact distribution, localization, and abundance of specific biomarkers under a light microscope. A 7-IHC panel utilizes a customized selection of seven distinct monoclonal or polyclonal antibodies tailored to a patient’s specific clinical presentation. This diagnostic tool is of paramount importance in modern oncology, surgical pathology, and personalized medicine, providing critical diagnostic, prognostic, and therapeutic insights that standard hematoxylin and eosin (H&E) staining cannot resolve.

The fundamental technology of immunohistochemistry involves tissue sectioning, antigen retrieval, primary antibody binding, secondary antibody-enzyme conjugation, and chromogenic visualization. When the customized antibodies bind to their target antigens in the tissue section, a chemical reaction produces a visible colored precipitate (usually brown or red). This allows the pathologist to determine whether specific proteins are expressed in the cell membrane, cytoplasm, or nucleus. The clinical value of a 7-IHC panel lies in its ability to classify undifferentiated tumors, determine the primary site of metastatic malignancies, differentiate benign from malignant lesions, and identify therapeutic targets for personalized cancer treatments, such as immunotherapy and hormone therapy.

Clinical Procedure: What to Expect

Patient Preparation

Because an Immunohistochemistry Panel (7-IHC) is performed on tissue samples that have already been obtained via biopsy or surgical resection, there is no direct physical preparation required for the patient at the time of laboratory processing. However, ensuring the integrity of the specimen and providing accurate clinical history is vital. Patients and referring physicians must observe the following guidelines:

• Submission of Tissue Blocks and Slides: Patients must submit the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block (often referred to as the “paraffin block”) along with the corresponding hematoxylin and eosin (H&E) stained slides from the initial biopsy.
• Prior Histopathology Reports: A copy of the original histopathology report must be provided to help the pathologist select the most appropriate 7-antibody panel.
• Clinical History and Referral: Detailed clinical notes, including radiological findings, suspected primary tumor sites, and previous cancer treatments, should be submitted.
• Specimen Integrity: Ensure that the tissue block has been fixed in 10% neutral buffered formalin within the recommended cold ischemia time to prevent antigen degradation.

During the Procedure

The laboratory processing of a 7-IHC panel at Lahore PCR Lab involves a series of highly controlled, automated, and manual steps performed by experienced histotechnologists and evaluated by consultant pathologists:

• Sectioning: The submitted paraffin block is mounted on a microtome, and ultra-thin sections (typically 3 to 4 microns thick) are cut and mounted on specially charged glass slides to prevent tissue detachment.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents like xylene and descending grades of alcohol to remove the paraffin wax and rehydrate the tissue.
• Antigen Retrieval: Formalin fixation causes protein cross-linking, which can mask target antigens. The slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions in a pressurized decloaking chamber to expose the target proteins.
• Antibody Incubation: The tissue sections are incubated with the seven selected primary antibodies. Each antibody is targeted against a specific cellular marker.
• Detection and Visualization: A secondary antibody conjugated with an enzyme (such as Horseradish Peroxidase) is applied, followed by a chromogen substrate (such as Diaminobenzidine). This produces a visible brown stain at the site of antigen-antibody binding.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to visualize cellular nuclei, dehydrated, and sealed with a coverslip.
• Microscopic Evaluation: A Consultant Pathologist examines the slides under a high-resolution light microscope to assess the staining pattern, intensity, and percentage of positive cells.

When is an Immunohistochemistry Panel (7-IHC) Performed?

Characterization of Undifferentiated Malignancies

When a biopsy reveals a highly malignant tumor that has lost its normal cellular characteristics (anaplastic or undifferentiated), standard microscopic examination cannot determine whether the tumor is a carcinoma, lymphoma, sarcoma, or melanoma. Physicians request a 7-IHC panel containing broad lineage markers (such as Cytokeratins, CD45, Vimentin, and S100) to categorize the tumor accurately. This differentiation is critical because the treatment protocols for these major cancer categories differ fundamentally.

Identifying the Primary Site of Metastatic Tumors

In patients presenting with metastatic cancer where the primary tumor site is unknown (Cancer of Unknown Primary or CUP), a 7-IHC panel is essential. By evaluating organ-specific transcription factors and cytokeratin expression patterns (such as CK7, CK20, TTF-1, CDX2, and GATA3), the pathologist can trace the origin of the metastatic cells. For instance, a lung metastasis showing positivity for TTF-1 suggests a primary lung adenocarcinoma, whereas positivity for CDX2 points to a gastrointestinal origin.

Subtyping Lymphoproliferative Disorders

Lymphomas are highly diverse malignancies of the immune system that require precise subtyping for effective treatment. A 7-IHC panel utilizing lymphoid markers (such as CD3, CD20, CD30, CD15, CD5, CD10, and Cyclin D1) allows pathologists to distinguish between B-cell and T-cell lymphomas, and further classify them into specific subtypes like Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, or Hodgkin Lymphoma.

Determining Breast Cancer Receptor Status

For patients diagnosed with breast carcinoma, a specialized 7-IHC panel is utilized to evaluate prognostic and predictive biomarkers. This panel typically includes Estrogen Receptor (ER), Progesterone Receptor (PR), HER2/neu, and Ki-67, along with basal markers like CK5/6 or p63. The results directly dictate whether the patient will benefit from hormone therapy (such as tamoxifen), targeted anti-HER2 therapy (such as trastuzumab), or systemic chemotherapy.

Predicting Prognosis and Targeted Therapy Response

Oncologists request IHC panels to evaluate specific therapeutic targets and prognostic indicators in various solid tumors. Markers like PD-L1 (Programmed Death-Ligand 1) help determine eligibility for immunotherapy, while mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) are evaluated to detect microsatellite instability (MSI) in colorectal and endometrial cancers, guiding both hereditary screening and treatment selection.

What Does an Immunohistochemistry Panel (7-IHC) Detect?

The 7-IHC panel can detect a wide array of specific cellular antigens, including:

• Pan-Cytokeratin (AE1/AE3): An intermediate filament marker indicating epithelial differentiation, positive in carcinomas.
• Leukocyte Common Antigen (LCA / CD45): A cell surface glycoprotein expressed on hematolymphoid cells, confirming lymphoma or leukemia.
• S100 Protein: Expressed in cells of neural crest origin, highly sensitive for melanoma, schwannoma, and neurofibroma.
• Vimentin: An intermediate filament characteristic of mesenchymal cells, positive in sarcomas and some carcinomas undergoing epithelial-mesenchymal transition.
• Estrogen Receptor (ER): A nuclear receptor indicating hormone-sensitive breast or gynecological malignancies.
• Progesterone Receptor (PR): A nuclear receptor that works in conjunction with ER to predict hormone therapy response.
• HER2/neu (ErbB2): A membrane glycoprotein overexpressed in a subset of breast, gastric, and gastroesophageal cancers.
• Ki-67: A nuclear protein expressed in active phases of the cell cycle, indicating the tumor proliferation index.
• Thyroid Transcription Factor-1 (TTF-1): A nuclear protein positive in primary lung adenocarcinomas and thyroid neoplasms.
• CD20: A cell surface marker specific to B-lymphocytes, positive in B-cell lymphomas.
• CD3: A T-cell receptor-associated marker, positive in T-cell lymphomas.
• Synaptophysin: A glycoprotein found in synaptic vesicles, indicating neuroendocrine differentiation.
• Chromogranin A: An acid soluble protein found in secretory granules of neuroendocrine cells.
• Desmin: An intermediate filament found in skeletal, smooth, and cardiac muscle cells, positive in rhabdomyosarcomas and leiomyosarcomas.
• Smooth Muscle Actin (SMA): Positive in smooth muscle tumors and myofibroblastic lesions.
• Prostate-Specific Antigen (PSA): A marker highly specific for prostatic tissue, confirming metastatic prostate adenocarcinoma.
• CD30: Positive in Reed-Sternberg cells of Hodgkin Lymphoma and anaplastic large cell lymphomas.
• CD15: Used in conjunction with CD30 to diagnose classical Hodgkin Lymphoma.
• Melan-A (MART-1): A lineage-specific antigen highly specific for melanocytic differentiation.
• Calretinin: A calcium-binding protein positive in mesotheliomas, helping differentiate them from adenocarcinomas.
• Cytokeratin 7 (CK7): Positive in glandular epithelia of the lung, breast, and gynecological tract.
• Cytokeratin 20 (CK20): Positive in mucosal epithelia of the gastrointestinal tract and urothelium.
• p63: A nuclear marker for basal cells, used to confirm invasion in breast and prostate biopsies.
• GATA3: A transcription factor positive in breast and urothelial carcinomas.
• PAX8: A nuclear transcription factor positive in renal, thyroid, and Müllerian (ovarian/endometrial) tumors.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely and accurate histopathology reporting is critical for oncology patients waiting to start treatment. Because an Immunohistochemistry Panel (7-IHC) is a complex, multi-step process involving tissue sectioning, automated staining, and detailed microscopic analysis by a Consultant Pathologist, the typical turnaround time is 3 to 5 working days from the receipt of the tissue block and slides. Once the report is finalized and signed off by our consultant histopathologist, patients receive an automated SMS notification. Reports can be securely downloaded from the official Lahore PCR Lab online portal, or collected physically from our main diagnostic center in Lahore.

Immunohistochemistry Panel (7-IHC) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Epithelial Markers (e.g., Pan-CK, CK7, CK20)	Negative in non-epithelial tissues; normal distribution in healthy epithelia.	Aberrant expression patterns indicating carcinoma, or specific CK7/CK20 profiles suggesting metastatic origin.
Lymphoid Markers (e.g., CD45, CD20, CD3)	Restricted to normal lymphoid organs and inflammatory cells.	Monoclonal or diffuse overexpression indicating B-cell or T-cell lymphoma.
Melanocytic Markers (e.g., S100, Melan-A)	Negative in epithelial and mesenchymal tissues; normal melanocytes positive.	Diffuse, strong positivity in undifferentiated tumors, confirming malignant melanoma.
Mesenchymal Markers (e.g., Vimentin, Desmin, SMA)	Normal expression in connective tissue, blood vessels, and muscle fibers.	Strong expression in undifferentiated tumors indicating sarcoma or myofibroblastic differentiation.
Neuroendocrine Markers (e.g., Synaptophysin, Chromogranin)	Positive only in normal endocrine and neuroendocrine cells.	Diffuse positivity in tumors, confirming neuroendocrine carcinoma or carcinoid tumor.
Hormone Receptors (ER, PR)	Normal physiological expression in breast and endometrial glandular cells.	Overexpression in breast carcinoma (predicts response to endocrine therapy) or loss of expression in high-grade tumors.
Oncogene Expression (HER2/neu)	Normal low-level expression (Score 0 or 1+).	Membranous overexpression (Score 3+), indicating HER2-positive breast or gastric cancer.
Proliferation Index (Ki-67)	Low expression in stable tissues; variable in physiologically active tissues.	Elevated Ki-67 percentage (e.g., >30%), indicating a highly proliferative, aggressive malignancy.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for Immunohistochemistry Panel (7-IHC)?

• Experienced Healthcare Professionals: Our histopathology department is led by highly qualified consultant pathologists with extensive experience in oncological pathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient well-being, ensuring that tissue samples are handled with the utmost care and respect.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international laboratory standards and quality control protocols.
• Professional Reporting: Our IHC reports are comprehensive, detailed, and structured to provide clear, actionable information for oncologists.
• Modern Diagnostic Approach: We utilize advanced automated staining platforms that ensure high reproducibility, minimal background staining, and precise results.
• Comfortable Environment: Our sample collection centers in Lahore offer a professional, clean, and welcoming environment for patients submitting specimens.
• Convenient Location: Located centrally in Lahore, our main laboratory is easily accessible for patients and courier services.
• Commitment to Accurate Diagnosis: We understand the critical nature of cancer diagnostics and are dedicated to providing the most accurate results to guide life-saving treatments.